MICROBOT MEDICAL INC

Company Overview

Microbot Medical is a clinical-stage medical device developer of the LIBERTY® endovascular robotic surgical system — a compact, fully disposable, remotely operated robot aimed initially at peripheral interventional radiology with planned extensions into interventional cardiology and neuroradiology. The company is pre-revenue and R&D/regulatory milestone driven: it has completed extensive preclinical work, an IDE filing (Jan 2024), a human clinical trial, a 510(k) submission (Dec 2024) and expects potential U.S. clearance in 2025 while pursuing CE Mark by 2026. Microbot outsources manufacturing to contract partners, holds an IP portfolio co‑owned with Technion (subject to 1.5–3.0% royalty on net sales), operates a small headcount split between the U.S. and Israel, and faces dependencies including regulatory outcomes, contract manufacturer transfer, supplier reliability and geopolitical exposure from Israeli operations. Recent financings materially strengthened liquidity in 2025 but the company remains subject to cash‑burn cycles tied to regulatory and commercialization milestones.

Executive Compensation Practices

Given Microbot’s pre‑commercial status and constrained near‑term cash needs, executive pay is likely equity‑heavy with a meaningful portion of value tied to stock options, warrants and milestone‑contingent awards rather than large cash bonuses. The MD&A documents increased R&D and G&A spending in 2024 driven in part by restored salary and bonus programs, suggesting a mix of modest cash compensation plus performance bonuses tied to regulatory and clinical milestones (IDE/510(k)/FDA clearance, CE Mark, successful transfer to contract manufacturing and commercialization readiness). Long‑term incentives will likely be structured to reward achievement of regulatory approvals, manufacturing scale‑up, and initial commercial KPIs (first sales, adoption by KOLs, share of targeted peripheral markets), while royalty obligations and co‑ownership of critical IP may reduce net margins and therefore influence bonus metrics. Expect continued use of stock options/warrants as a compensation lever (and as a retention tool for a small technical team), with careful structuring to manage dilution and accounting classifications (ASC 480/815 impacts noted in filings).

Insider Trading Considerations

Insider activity is likely to cluster around financing events and regulatory milestones: the company’s 2025 equity raises and option exercises already produced notable insider-related flows, and future Form 4 filings should be monitored closely around IDE/510(k)/clearance announcements. Because executives hold equity and are frequently compensated with options/warrants, look for option exercises followed by sales to cover taxes or liquidity needs — these can produce temporary sell pressure even when company prospects improve. Standard sector and SEC rules apply: officers and directors are subject to Section 16 reporting and short‑swing profit rules, blackout periods prior to material disclosures are common, and executives may use Rule 10b5‑1 plans to pre‑arrange sales; verifying whether trades are part of 10b5‑1 plans is important. Finally, the company’s Israeli operations and supplier risks mean non‑regulatory operational disclosures (supply disruption, geopolitical developments) can also prompt insider trading, so monitor both clinical/regulatory and geopolitical updates.